Gufic Biosciences Limited (BOM:509079)

Market Cap	36.40B
Revenue (ttm)	8.41B
Net Income (ttm)	618.64M
Shares Out	100.28M
EPS (ttm)	6.17
PE Ratio	58.84
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 17, 2024

Volume	4,405
Average Volume	3,416
Open	375.30
Previous Close	375.10
Day's Range	366.05 - 375.50
52-Week Range	285.00 - 501.10
Beta	0.14
RSI	45.92
Earnings Date	Aug 13, 2025

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,491
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In 2024, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.